Novo Nordisk

Entelechy Expands Global Footprint with Key Partnerships and Local Language Facilitation Capabilities

Retrieved on: 
Monday, April 4, 2022
DIRECTV, Social learning, Investment, Staples, Program, Novo Nordisk, Comcast, Industry, Thermo Fisher Scientific, Quality Practice Award, Republic Services, Leadership, RingCentral, HCM, Learning, Partnership, Management

This development comes as a result of increased global demand for the company's award-winning Unleash Your Leadership Potential program, a comprehensive leadership development program for frontline and mid-level managers.

Key Points: 
  • This development comes as a result of increased global demand for the company's award-winning Unleash Your Leadership Potential program, a comprehensive leadership development program for frontline and mid-level managers.
  • Fortifying the company's facilitation capabilities is a natural extension of significant investments made by the organization to offer clients world-class virtual learning experiences.
  • Entelechy is also bringing Unleash Your Leadership Potential to global leaders through its ongoing strategic partnership with NovoEd , a leader in collaborative learning platforms.
  • Entelechy's flagship leadership development programs, Unleash Your Leadership Potential and Leading Leaders, transform leaders as they progress through their careers.

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

Retrieved on: 
Monday, April 4, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Therapy, Trust law, Bacteriophage, European Commission, MD, Royal commission, Technology, Johnson & Johnson, Time, US, UCB, National, Novo Nordisk Foundation, Investigational New Drug, United States Department of Defense, Bacteria, Â, Mayo Clinic, Boehringer Ingelheim, NIH, Eli Lilly and Company, DFO, European Investment Bank, World Health Organization, Merck Group, AMR, Multimedia, Doctor of Philosophy, World, Wellcome Trust, FDA, Fund, Patient, Partnership, Daiichi Sankyo, List of international sports federations, Medication, Leo Pharma, APT, Novo Nordisk, Infection, Pharmaceutical industry, Antibiotics, Takeda, GlaxoSmithKline, Eisai, Amgen, Pfizer, Lundbeck, Bayer, Merck, Novartis, Teva, Chugai Pharmaceutical Co., Shionogi

Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.

Key Points: 
  • Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor.
  • View the full release here: https://www.businesswire.com/news/home/20220404005289/en/
    We are very pleased to welcome the AMR Action Fund as an investor, stated Greg Merril, Chief Executive Officer and Co-Founder of APT.
  • In addition to their capital, the AMR Action Fund adds significant strategic value, including advisory and scientific support.
  • The AMR Action Fund is the worlds largest public-private partnership investing in antibiotics, antifungals, and other antimicrobial treatments.

uStudio Integrates Enterprise Podcasting into Microsoft 365

Retrieved on: 
Wednesday, March 30, 2022
Technology, Other Communications, Human Resources, Entertainment, Other Technology, Online, Communications, Professional Services, Software, Audio, Video, SharePoint, Health, Growth, 7-Eleven, Alcon, CTO, Comment, Industry, Microsoft Bing, Universal Music Group, Nike, Netflix, Boston Consulting Group, DE, Novo Nordisk, Partnership, Video game console, Online shopping, Microsoft, TEAMS

uStudio, a leading platform in streaming media and podcasting for the enterprise, announced today new integration with Microsoft 365. uStudio customers can now use Microsoft SharePoint, Teams, and Search to discover and access enterprise audio and video podcast content on the uStudio platform.

Key Points: 
  • uStudio, a leading platform in streaming media and podcasting for the enterprise, announced today new integration with Microsoft 365. uStudio customers can now use Microsoft SharePoint, Teams, and Search to discover and access enterprise audio and video podcast content on the uStudio platform.
  • uStudios new integration comes on the heels of growth in the enterprise podcasting industry.
  • Since podcasts can be played anytime, anywhere, uStudio gives time-shifted and multi-tasking workers an alternative to emails, newsletters and live video meetings.
  • uStudio, Inc. does not have any type of partnership, relationship, or affiliation with Microsoft.

Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes

Retrieved on: 
Monday, March 28, 2022
Food, American Diabetes Association, Exercise, Risk, US Foods, Diet, Type 2 diabetes, Stroke, FDA, Joint Medical Service (Germany), Novo Nordisk, Death, Dietary supplement, Pharmaceutical industry, Semaglutide

PLAINSBORO, N.J., March 28, 2022 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.2 Ozempic® is not a weight loss drug, but may help people lose some weight. Ozempic® will be available in three therapeutic doses (0.5 mg, 1 mg, and 2 mg) to help people with type 2 diabetes reach their blood sugar (A1C) goal, now including those with a higher A1C who have been unable to meet their A1C target.

Key Points: 
  • Novo Nordisk expects to launch Ozempic 2 mg in the United States shortly.
  • Ozempic(semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:
    along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
  • to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes mellitus with known heart disease.
  • It is not known if Ozempic is safe and effective for use in children under 18 years of age.

Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020

Retrieved on: 
Monday, March 28, 2022
Novo Nordisk Foundation, Novozymes, Seed, NASDAQ, BBI, Russia in the European energy sector, Novo Holdings A/S, Income, Investment, Return, Growth, Novo Nordisk, Research, CEO, Health, Initial public offering, DKK, Foundation, Solution, IPO, Partnership, Fine chemical, Financial services, Sungard Availability Services

COPENHAGEN, Denmark, March 28, 2022 /PRNewswire/ --Novo Holdings realised Total Income and Returns of DKK 37 billion (5 billion) in 2021, representing a 29% increase over 2020.

Key Points: 
  • COPENHAGEN, Denmark, March 28, 2022 /PRNewswire/ --Novo Holdings realised Total Income and Returns of DKK 37 billion (5 billion) in 2021, representing a 29% increase over 2020.
  • Novo Holdings closed 2021 with total assets of DKK 697 billion (94 billion), up from DKK 457 billion (61 billion) in 2020, with the Novo Holdings Investment Portfolio alone increasing to a record DKK 182 billion (24 billion).
  • The Novo Holdings Investment Portfolio comprises Life Science Investments (Novo Seeds, Novo Growth, Novo Ventures and Novo Principal Investments), making up 52% of the portfolio, and Novo Capital Investors (48% of the portfolio).
  • The Life Science Investment Portfolio and Novo Capital Investors contributed evenly with returns of close to DKK 12 billion (1.6 billion) each.

Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020

Retrieved on: 
Monday, March 28, 2022
Novo Nordisk Foundation, Novozymes, Seed, NASDAQ, BBI, Russia in the European energy sector, Novo Holdings A/S, Income, Investment, Return, Growth, Novo Nordisk, Research, CEO, Health, Initial public offering, DKK, Foundation, Solution, IPO, Partnership, Fine chemical, Financial services, Sungard Availability Services

COPENHAGEN, Denmark, March 28, 2022 /PRNewswire/ --Novo Holdings realised Total Income and Returns of DKK 37 billion (5 billion) in 2021, representing a 29% increase over 2020.

Key Points: 
  • COPENHAGEN, Denmark, March 28, 2022 /PRNewswire/ --Novo Holdings realised Total Income and Returns of DKK 37 billion (5 billion) in 2021, representing a 29% increase over 2020.
  • Novo Holdings closed 2021 with total assets of DKK 697 billion (94 billion), up from DKK 457 billion (61 billion) in 2020, with the Novo Holdings Investment Portfolio alone increasing to a record DKK 182 billion (24 billion).
  • The Novo Holdings Investment Portfolio comprises Life Science Investments (Novo Seeds, Novo Growth, Novo Ventures and Novo Principal Investments), making up 52% of the portfolio, and Novo Capital Investors (48% of the portfolio).
  • The Life Science Investment Portfolio and Novo Capital Investors contributed evenly with returns of close to DKK 12 billion (1.6 billion) each.

SparkCognition Delivers Visual AI Capabilities Across Industries With Acquisition of Integration Wizards

Retrieved on: 
Friday, March 25, 2022
Organization, CCTV, Xerox, Leadership, Investment, Novo Nordisk, Hindustan Petroleum, Automation, Heineken, CGM, Fortune 500, HPCL, CEO, Intelligence, Entrepreneurship, Natural language processing, Artificial intelligence, OT, Industry, Technology, Safety, Reliance Industries, Machine learning, Solution, AI, Deep learning, Acquisition, IP, Medical device

AUSTIN, Texas, March 25, 2022 /PRNewswire/ -- SparkCognition, a global leader in artificial intelligence (AI) software solutions perfected for business, is pleased to announce it has signed a definitive agreement to acquire Integration Wizards, a leader in visual AI. Through this acquisition, SparkCognition expands its IP portfolio to include computer vision capabilities, bringing greater value to its industry solutions. The technology leverages new and diverse data sets, including CCTV feeds, drone footage, video from handheld devices, and existing camera infrastructures. The solution can be deployed in hours or days, and helps address critical problems, including safety, security, visual inspection, productivity, and situational awareness.

Key Points: 
  • Through this acquisition, SparkCognition expands its IP portfolio to include computer vision capabilities, bringing greater value to its industry solutions.
  • "Integration Wizards has delivered visual AI at scale for innovators and Fortune 500 customers alike, saving lives, safeguarding assets, and driving demonstrable productivity gains."
  • Since its inception in 2014, Integration Wizards' visual AI technology has provided solutions to global organizations including Hindustan Petroleum, Reliance Industries Limited, Heineken, Xerox, Novo Nordisk, and Johnson Controls.
  • "The breadth of SparkCognition's AI solutions and services, coupled with our extensive experience in deploying Visual AI capabilities to Fortune 500 customers, will be a game changer."

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Retrieved on: 
Monday, March 21, 2022
Company, Amyotrophic lateral sclerosis, Chlamydia trachomatis, Clonidine, NASDAQ, U.S. FDA, Diagnosis, Marketing, Risk, Forward-looking statement, Clinical trial, Toronto Stock Exchange, Arginine, Legislation, Adult, European Commission, ALS, PD, Neuromyelitis optica spectrum disorder, Parkinson's disease, Severe acute respiratory syndrome coronavirus 2, EudraCT, Growth hormone, TSX, Safety, Time, COVID-19, GLOBE, Union, Hypoparathyroidism, News, NMOSD, Annual report, FDA, Novo Nordisk, Patient, Pharmaceutical industry, Ludwig & Mayer

TORONTO, ONTARIO, March 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today provided an update for its ongoing pivotal Phase 3 safety and efficacy study AEZS-130-P02 (the “DETECT-trial") evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency (CGHD).

Key Points: 
  • The DETECT-trial is a multicenter, open-label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (GHST) in pediatric patients with suspected growth hormone deficiency (GHD).
  • Children and adolescents from two to less than 18 years of age with suspected growth hormone deficiency are to be included.
  • The macimorelin GHST will be performed twice for repeatability data and two standard GHSTs will be used as controls: arginine (i.v.)
  • The Company's lead product, macimorelin (Macrilen), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Mozart Therapeutics Announces Appointment of Jan Beck as Chief Operating Officer

Retrieved on: 
Monday, March 21, 2022
Inflammation, Therapy, LinkedIn, Degenerative disease, Leadership, Autoimmunity, Head, Pathology, List of life sciences, Association, CD8, Novo Nordisk, Disease, Pharmaceutical industry, Management, Vaccine, Wolfgang Amadeus Mozart

SEATTLE, March 21, 2022 /PRNewswire/ -- Mozart Therapeutics , a leading developer of CD8 Treg modulators targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announcedthe appointment of Jan Beck as Chief Operating Officer.

Key Points: 
  • SEATTLE, March 21, 2022 /PRNewswire/ -- Mozart Therapeutics , a leading developer of CD8 Treg modulators targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announcedthe appointment of Jan Beck as Chief Operating Officer.
  • At Mozart, Mr. Beck will oversee corporate development, portfolio and alliance management, finance, and business operations.
  • "Jan is an excellent addition to the executive leadership team, and his broad expertise and proven track record will be instrumental to Mozart as we advance our pipeline of disease modifying therapeutics toward the clinic" said Katie Fanning, President and Chief Executive Officer at Mozart Therapeutics.
  • Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway.

Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 17, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Bristol Myers Squibb, Patient, Euronext Paris, Tumor microenvironment, IPHA, Novo Nordisk, AstraZeneca, Antibody, CET, IPH, Company, Cancer, Telephone, Webcast, Immune system, Investor, Sanofi, Vaccine, Fine chemical, MD, Nasdaq

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m.
  • ET, following the release of its financial results for the full year ending December 31, 2021.
  • A replay of the webcast will be available on the Company website for 90 days following the event.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.